Atopic Dermatitis

A new report delves into the case of a 35-year-old man with ARPC and why dupilumab was utilized for treatment.

James Song, MD, shares a comprehensive guide to what is new, what is now, and what is next in AD treatment.

Mickey Bryson describes the impact of atopic dermatitis on his quality of life and family, and the session concludes with final reflections.

A recent study demonstrated the benefits and limitations of PatientsLikeMe for patients with atopic dermatitis and other skin conditions.

A dermatology expert reviews findings from a recently presented study on using other atopic dermatitis (AD) treatments within six months of initiating ruxolitinib cream. The expert assesses ruxolitinib's effectiveness and potential role in treatment, highlighting the need for further research on its long-term implications in AD management.

Bradley Burnam discusses results from an in-vivo model of atopic dermatitis.

Focusing on pregnant patients with atopic dermatitis who are treatment naïve, Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, discuss best practices for informing patients on the available treatment options for this condition.

Jenny Murase, MD, provides a brief overview of the Fc receptor and the role of transcription binding in atopic dermatitis.

Ensemble No.2, or ENS-002, is an investigational live biotherapeutic product first detected by Concerto Biosciences using its kChip technology.

Authorization for Eli Lilly's Ebglyss is based on positive results from the ADvocate 1, ADvocate 2, and ADhere studies.

Mickey Bryson recounts how Kristine Kucera, PA-C, MPAS, DHS, introduced a new medication and shared trial data with him, empowering him to make an informed decision about trying the new treatment.

James Del Rosso, DO, continues the discussion on managing acne in a female patient, emphasizing how to balance patient expectations and optimize skincare regimens, particularly when underlying conditions like polycystic ovarian syndrome are present.

An acne management expert discusses the importance of understanding patients' dietary choices on treatment outcomes, reviewing the different types of isotretinoin and highlighting the crucial role of micronized or food-independent formulations in effective acne care.

James Del Rosso, DO, presents the case of a 14-year old female suffering from mild to moderate acne and explores the role of isotretinoin, optimizing adolescent treatment protocols, and the rationale behind initial therapies such as oral antibiotics in similar cases.

The post-hoc analysis evaluated the relationship between lebrikizumab serum concentration levels and sustained clinical response after lebrikizumab discontinuation.

Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation of ruxolitinib therapy.

Dermatologists provide clinical insights on how they discuss atopic dermatitis treatment options, considerations, and safety concerns with patients who are pregnant or of childbearing age.

Jenny Murase, MD, describes how rising estrogen levels cause a shift in immune response from Th1 to Th2, causing potential atopic dermatitis exacerbations for patients who are pregnant.

Eli Lilly recently hosted a panel discussion with Olympic athlete Suni Lee to discuss the importance of finding a dermatologist who understands the burden of AD.

Kristine Kucera, PA-C, MPAS, DHS, and Mickey Bryson discuss Mickey's negative treatment outcomes and explore alternative options, such as switching to a psoriasis-specific medication, emphasizing the short-lived 2-week relief followed by symptom recurrence, which left Mickey resigned to the disease but still seeking a resolution.

A recent study found that AD not only affects mental health and QoL, but women’s sexual health and gestational desires as well.

An expert in the management of dermatological conditions shares insights on managing atopic dermatitis patients, discussing the real-world effectiveness and physician satisfaction with ruxolitinib cream as a treatment option, as well as its adoption among healthcare providers.

LEO Pharma's Adbry, a single-dose autoinjector, is expected to become available to patients in the coming months.

Experts on atopic dermatitis discuss the importance of open dialogue with patients who are pregnant or of childbearing potential regarding the safety concerns associated with treatments for this condition.

Dr. Elizabeth Kiracofe, MD, FAAD, and Dr. Jenny Murase, MD, introduce a discussion on the undertreatment of patients with atopic dermatitis, particularly focusing on pregnant individuals and those of childbearing age.